Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).
CD30+ anaplastic large cell lymphoma is a primary cutaneous lymphoproliferative disorder with a high rate of spontaneous regression (almost 25%). The suggested therapies are radiation, surgery and methotrexate. We describe two patients with nonregressing primary cutaneous CD30+ T-cell lymphoma that was successfully treated with topical imiquimod 5% cream (Aldara, 3M) three times weekly for 6 weeks. In both cases we obtained complete clinical remission, confirmed by histology. No recurrences were observed during the following 8 months. We consider that topical application of an immune response modifier, such as imiquimod, could be a good alternative to other potentially more dangerous or aggressive treatments.
Didona
B
B
Department of Dermatological Sciences, Istituto Dermopatico dell'Immacolata-IRCCS, 00167 Rome, Italy.
Benucci
R
R
Amerio
P
P
Canzona
F
F
Rienzo
O
O
Cavalieri
R
R
D000287:Administration, Topical; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016207:Cytokines / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D000077271:Imiquimod; D007371:Interferon-gamma / Q000276:immunology; D017730:Ki-1 Antigen / Q000032:analysis; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D016207:Cytokines; D017730:Ki-1 Antigen; D007371:Interferon-gamma; D000077271:Imiquimod